FOLH1 and prostate carcinoma: The introduction of PSMA-PET imaging has led to significant improvements in the staging, restaging, and treatment planning for prostate cancer patients, and PSMA-based theranostics have recently gained approval from the Food and Drug Administration (FDA) [6].